UPDATE: Jefferies Raises PT on Amarin Corporation from $26 to $28

Jefferies reiterated a Buy rating on Amarin Corporation

and increased its price target from $26 to $28. Jefferies commented, “AMRN announced that it had received an intention to grant letter for a European AMR101 patent application that covers the findings from the MARINE trial. We believe this issuance is an incremental positive for AMRN, as it means the potential for European market exclusivity into 2029.” Amarin closed at $14.58 on Wednesday.